Bio-Techne Announces Changes to its Leadership Team

Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026. Dr. Matt McManus will transition from his role as President, Diagnostics and Spatial Biology Segment and will remain with the company temporarily to support a smooth transition. Steve Crouse is appointed President, Diagnostics and Spatial Biology Segment.

Steve Crouse joins from Bio-Techne's Analytical Solutions Division, brings over 20 years of industry experience, and is credited with launching platforms and delivering strong growth during his four-year tenure at Bio-Techne.

Management said McManus played a key role in organizational optimization, including the strategic divestiture of the Exosome business.

Positive

• New president appointment effective March 1, 2026
• Steve Crouse brings 20+ years of life sciences leadership
• Crouse credited with launching innovative platforms and driving growth

Negative

• Leadership transition could cause short-term operational or strategic disruption

Argus Feb 11 session

-2.08% close to close Open Argus

Details

News Market Reaction – TECH

In the Feb 11 session, TECH declined 2.08%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a planned leadership transition in Bio‑Techne’s Diagnostics and Spatial Bi...

Analysis

This announcement details a planned leadership transition in Bio‑Techne’s Diagnostics and Spatial Biology Segment, effective March 1, 2026, with an internal executive stepping into the president role. Recent filings show this segment’s margins improving alongside the Exosome divestiture, making execution under new leadership an important watchpoint. Investors may focus on how the new leader sustains growth in protein analysis instruments and immunoassays while maintaining operational efficiency.

Key Figures

Leadership transition date: March 1, 2026

Leadership transition date

March 1, 2026

Effective date for President, Diagnostics and Spatial Biology Segment change

Historical Context

5 past events · Latest: Feb 04

5 events

1. Feb 04

   Dividend declaration

   24h Move

   +6.3%

   Quarterly cash dividend of $0.08 per share with fiscal 2025 sales detail.

2. Feb 04

   Earnings release

   24h Move

   +6.3%

   Flat revenue but higher EPS and operating margins in Q2 FY2026.

3. Feb 02

   Product launch

   24h Move

   +1.8%

   Launch of Cultrex Synthetic Hydrogel for 3D stem cell and organoid culture.

4. Jan 28

   Product launch

   24h Move

   -3.9%

   Ultra-sensitive Ella assays for neurological biomarkers with faster workflows.

5. Jan 20

   Earnings call notice

   24h Move

   +1.3%

   Scheduling of February 4, 2026 conference call on Q2 FY2026 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunoassays

1 terms

immunoassays medical

"he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven"

Immunoassays are laboratory tests that use specially made immune proteins (antibodies) to find and measure specific molecules—like proteins, hormones or bits of a virus—in blood or other samples, similar to using a highly specific key to pick out one lock in a crowded room. Investors care because these tests drive sales of diagnostic devices and consumables, affect clinical trial and regulatory outcomes, and can create recurring revenue and competitive advantage for medical and biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
  
  
• Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026

MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.

Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment. 

Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit.  He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.

"Matt has played a key role in optimizing our organization, including driving the strategic divestiture of the Exosome business. I thank Matt for his strong leadership, positive impact on our business, and the legacy he leaves with our people, culture and innovation," said Kim Kelderman, President and Chief Executive Officer, Bio-Techne. "I'm delighted that Steve will be stepping up to take on the role of President, with his strong track record, visionary leadership, and over 20 years' experience in advancing innovative life science solutions making him an ideal fit for this role."  

Kelderman added, "I'm excited for Steve to work with Will Geist, President of Bio-Techne's Protein Sciences Segment, to drive Bio-Techne's next phase of growth."   

About Bio-Techne 
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube. 

Media contacts  

Corporate Communications  
media.relations@bio-techne.com  

David Clair, Vice President, Investor Relations  
david.clair@bio-techne.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-changes-to-its-leadership-team-302685129.html

SOURCE Bio-Techne Corporation

FAQ

Who is replacing Dr. Matt McManus as President of Diagnostics and Spatial Biology (TECH)?

Steve Crouse will replace Dr. Matt McManus as President, Diagnostics and Spatial Biology, effective March 1, 2026. According to the company, Crouse has over 20 years of industry leadership and led Bio-Techne's Analytical Solutions Division during a four-year tenure.

When does the Bio-Techne (TECH) leadership change take effect?

The leadership change takes effect on March 1, 2026. According to the company, Dr. Matt McManus will transition from his role and remain temporarily to support a smooth handover to Steve Crouse.

What is Steve Crouse's background before becoming President at Bio-Techne (TECH)?

Steve Crouse served as Senior Vice President of Bio-Techne's Analytical Solutions Division and led product platform launches. According to the company, he previously managed Thermo Fisher's Protein Detection and Quantification business unit and holds an MBA and M.S. in Biochemistry.

Will Dr. Matt McManus remain with Bio-Techne (TECH) after March 1, 2026?

Yes, Dr. Matt McManus will remain with the company for a period to support transition after March 1, 2026. According to the company, he helped drive organizational optimization including the strategic divestiture of the Exosome business.

Does the Bio-Techne (TECH) announcement mention strategic transactions tied to this leadership change?

The announcement references a prior strategic divestiture of the Exosome business linked to leadership efforts. According to the company, McManus played a key role in driving that divestiture as part of organizational optimization.